Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
02:20pm, Tuesday, 12'th May 2026
Axsome Therapeutics, Inc. (AXSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
3 Stocks Poised to Disrupt the Healthcare Market by 2030
07:30am, Friday, 08'th May 2026
The old healthcare model is breaking down.
Axsome Therapeutics Recognizes Mental Health Month
07:00am, Thursday, 07'th May 2026
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
01:50pm, Tuesday, 05'th May 2026
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
3 Overlooked Stocks Set to Soar in 2026
08:45am, Tuesday, 05'th May 2026
These relatively small biotechs have recent catalysts that haven't yet been fully priced into their stocks.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 05'th May 2026
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
03:43pm, Monday, 04'th May 2026
Axsome Therapeutics, Inc. (AXSM) Q1 2026 Earnings Call Transcript
Why Did Axsome Therapeutics Stock Hit Another Record High Today?
03:10pm, Monday, 04'th May 2026
Investors think a new addition to the biotech's pipeline could be the next catalyst.
Axsome Therapeutics Q1 2026 Earnings Review: Gains Mystify Me, But Can't Be Denied
12:32pm, Monday, 04'th May 2026
Axsome Therapeutics, Inc. is rated Hold, as revenue growth and pipeline promise are offset by sequential declines and ongoing losses. AXSM's Q1 revenues grew 57% year-on-year to $191m, but both Auveli
Here's What Key Metrics Tell Us About Axsome (AXSM) Q1 Earnings
10:30am, Monday, 04'th May 2026
Although the revenue and EPS for Axsome (AXSM) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street e
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue Estimates
09:15am, Monday, 04'th May 2026
Axsome Therapeutics (AXSM) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.8 per share a year ago.
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Monday, 04'th May 2026
Total 1Q 2026 net product revenue of $191.2 million, representing 57% year-over-year growth AUVELITY ® 1Q 2026 net product sales of $153.2 million, representing 59% year-over-year growth SUNOSI ® 1Q
Why Axsome Therapeutics Stock Jumped Over 20% in April
10:47am, Saturday, 02'nd May 2026
Axsome shares reached an all-time high last month, and there might be more to come.
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader
07:15am, Friday, 01'st May 2026
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host
